World Journal of Internal Medicine and Surgery
ISSN (O): 3048-510X ISSN (P): 3051-2565
Review Article
2026, Volume 3, Issue 3, Page: 20-25. www.wjims.com

# ARTIFICIAL INTELLIGENCE ROLE IN DRUG DISCOVERY AND DEVELOPMENT

Pasupuleti Sreenivasa Rao*[abc], Palukuru Sreenivasulu Reddy, Ramalinga Viswakumar

[1a]Professor, [1b]Senior Research Scientist, [1c]Research Advisory Professor, Department of Biochemistry Central Research Laboratory (ARC), Narayana Medical College, Narayana College of Pharmacy, Nellore-524003, Andhra Pradesh, India.
[2a]Professor and Dean, Department of Microbiology, Narayana Medical College.
[3a]Professor and Head, Department of Biochemistry, Narayana Medical College.

**Article Info**

Article Received: 05 March 2026,
Article Revised: 15 March 2026,
Published on: 01 April 2026.

***Corresponding author:**

**Pasupuleti Sreenivasa Rao**

Professor, Department of Biochemistry, Senior Research Scientist, Central Research Laboratory (ARC), Narayana Medical College and Hospital, Nellore-524003, Andhra Pradesh, India.
sraopasupuleti@yahoo.com

https://doi.org/10.5281/zenodo.19495815

**How to cite this Article:**
Pasupuleti Sreenivasa Rao, Palukuru Sreenivasulu Reddy, Ramalinga Viswakumar. (2026). "Artificial Intelligence Role In Drug Discovery And Development." World Journal of Internal Medicine and Surgery, 3(3), 20–25.



## ABSTRACT

Artificial intelligence (AI) has developed as a transformative tool in drug discovery development. Answering the limitations of traditional methods which are costly, time-consuming, and related with high rates of failure. With the advent of AI, advancements in machine learning (ML), deep learning (DL), and data-driven modeling have permitted effective assessment of large-scale biological, chemical, and clinical datasets. AI supports multiple phases of drug discovery, that includes target identification, hit discovery, lead optimization, and early prediction of pharmacokinetic and toxicity profiles. Further, AI-driven pipelines enhance decision-making by integrating diverse data and improving predictive accuracy. Techniques like genetic algorithms directly support to lead optimization by producing novel candid leads with better therapeutic potential. The integration of AI in clinical trial design and biomarker detection also helps in the development of personalized medicine. In spite of these benefits, tasks like data quality, model interpretability, and regulatory concerns stay significant. Answering these limitations through explainable AI and large scale data integration approaches is crucial for larger acceptance. Largely, AI has the potential to considerably speed up the drug discovery processes, by lowering the costs, and also enhancing success ratio rates, thereby progressing pharmaceutical research and allowing the development of new, safer and more, efficient therapeutic candid leads. Thus the present review highlights the importance of AI in drug discovery and development.

**KEYWORDS:** Artificial intelligence (AI) , Drug Discovery, algorithms.

## INTRODUCTION

Artificial Intelligence (AI) is a new branch of science, that focuses on designing intelligent machines and computer systems and also capable of carrying out tasks that naturally require human cognitive abilities, such as reasoning, learning, and decision-making.[1,2] This field attained major recognition in early1956, where first hypothesis was developed by the Logic Theorist Allen Newell and his colleagues, which is identified as the earliest functional AI programs.[3] From there, AI has evolved quickly, driven by major advancements in computational power, data availability, and development of various algorithms. AI systems are purposely designed to simulate various aspects of human intelligence, allowing computers and robotic systems to assess information, study their patterns, and to make informed decisions. AI has wider applications. For instance in case of drug development, AI stood as a potent tool, which is applied across multiple phases of pharmaceutical pipeline. The AI applications is useful in the early detection of novel drug targets, better understanding of disease mechanisms, and also helps in the discovery of potential novel biomarkers.[4]

Moreover, AI backs the analysis of difficult biological datasets, enabling insights that are tough to accomplish by conventional methods. Consequently, several pharmaceutical companies are progressively investing in AI-driven technologies, mainly in the areas that is connected with machine learning (ML), deep learning (DL), and also to improve data-driven execution processes.

The drug discovery and development division plays a major role in healthcare, which allows detection of novel therapeutic agents and new strategies for the treatment of varied range of diseases.[5] Moreover, the majority of the global population up to 80 percent in developed and as well as developing nations depend on traditional medicine for their primary health care. Currently, medicinal plant/herbal medicine for treating various disorders and diseases is rapidly emerging, since they offer less toxic side effects[6-7] The Medicinal /herbal Plants may encompass active constituents, which have been shown to efficiently hinder the disease or disorder symptoms in a synergistic manner. These active ingredients from these Medicinal /herbal plants may possess polysaccharides, pigments, steroids, terpenoids, flavonoids, alkaloids, etc. Earlier studies have shown that Medicinal/herbal plant extracts and purified molecules efficiently managed to control several diseases and disorders.[6-14] However, traditional approaches face sever hurdles in developing new drugs from natural resources. Thus new age strategies are required.

AI looks better alternative in the present scenario. Modern Genomics and bioinformatics tools connected to AI play a key role in better understanding the disease and disorders and further supports in drug discovery.[15-19] Nevertheless, the quick increase of digital data in the pharmaceutical industry has presented significant challenges connected to data management, integration, and interpretation.[20] Moreover, challenges is due to the diversity, volume, and complexity of biological, chemical, and clinical datasets. AI deals real solutions by allowing automated data processing, pattern recognition, and also through predictive modeling, thus improving efficacy and lowering the burden related with large-scale data analysis.[21] The major strengths of AI is to mimic human-like problem-solving and learning capabilities, with latest advanced algorithms, which can identify unseen relationships within data, optimize processes, and produce predictive insights.[22] The uninterrupted development of innovative AI tools, mixed with improved computational resources, has the potential to enhance and modernize drug discovery and development programmes considerably. In spite of these developments, the pharmaceutical and medical device industries remain to face fresh challenges that includes declining productivity in drug development, followed by increase in budget allocated to research and development.[23] These factors highlight the importance and immediate need of innovative approaches that includes AI integration, to progress overall efficacy and also to enhance success rates.

The current pharmaceutical industry comprises a wide range of activities that includes research in identifying new drugs, developing new formulations, manufacturing, and distribution. Drug discovery is the primary step, which has sigficance in identifying potential drug molecules. These molecules undergo preclinical assessment, followed by clinical trials to measure their safety, efficacy, dosage, and acceptability.[24] If effective, the drug is placed under regulatory approval authorities like NDA (New Drug Application) for further processing. In spite of technological developments, the process of drug discovery is still extensive, expensive, and linked with low rates of success. Averagely, it requires nearly10–12 years for a candid lead to a potential drug from early discovery to market approval.[25] Besides, only a minor proportion of candidate leads will successfully complete clinical trials. This small success rate highlights its importance and pressing need to enhance the efficacy, precision, and probability of drug discovery processes. In this background, AI has appeared as an amicable solution to these challenges, by permitting fast data analysis, advancing predictive modeling, and enhancing decision-making. Moreover, AI technologies have the capacity in accelerating drug discovery programmes in stipulated time and also in within in the budget limits. Therefore, the integration of AI into pharmaceutical research is need of the hour, which is vital, and will pave a way for more effective and innovative new drug development approaches. Thus the present review highlights the importance of AI in drug discovery and development.

**Applications of Artificial Intelligence in Drug Discovery**

Figure 1 clearly demonstrates the wide range of applications of Artificial Intelligence (AI) across multiple steps in the drug discovery process. In the figure-1, presenting AI, as a central computational system that integrates many biological, chemical, and clinical datasets to ease intelligent decision-making.[1,2] On both sides of central unit, few key application domains are placed in sequence that highlight the versatility and impact of AI in pharmaceutical research. The initial applications determined in figure1 is **target identification and validation**, where AI algorithms will assess genomic, proteomic, and transcriptomic data to identify potential biological targets that are related with specific diseases.[4] Machine learning models can capably process huge datasets to find hidden patterns and prioritize targets based on their therapeutic importance. The next application is **hit and lead discovery**, where AI is employed to screen large chemical libraries and detect potential candid leads with potential biological activity.[5] Virtual screening approaches empowered by AI considerably reduces the time and budget in comparison with traditional high-throughput screening methods. In addition, **de novo drug design** allows the production of novel molecular structures by deep learning and generative models, increasing the chemical space beyond identified molecules.[26]

Further, the other application in the figure-1 describes about **ADMET prediction (Absorption, Distribution, Metabolism, Excretion, and Toxicity)**, which is a vital step in assessing drug safety and efficacy. AI models easily predicts pharmacokinetic and toxicity profile at initial stage in the drug development process, so reducing late-stage failures.[27-28] Also, **biomarker identification** plays a key role in personalized medicine, where AI supports to discover diagnostic and prognostic biomarkers from complex biological datasets.[22] Next coming to an important application is **clinical trial optimization**, where AI betters patient selection, trial design, and result prediction.[22] By studying historical clinical data, AI can improve trial efficiency and lower failure rates. Additionally, AI allows for better **understanding disease mechanisms** by integrating multi-omics data and recognising important pathways involved in disease progression.[29] Largely, Figure 1 highlights that AI is not restricted to a single stage but rather extents to the complete drug discovery pipeline. Its capability to manage large-scale data, recognise complex relationships, and produce predictive insights makes it an essential tool in the present day pharmaceutical research. The integration of AI, particularly in these domains significantly improves efficacy, reduces budget, and speed up the development process of innovative new therapeutics.[21-22]

**AI-Driven Pipeline in Drug Discovery**

AI-driven drug discovery pipeline documented in Figure2. It demonstrates Integration of AI at each step of the drug discovery process to develop efficacy and accuracy. The pipeline initiates with **collection of data**, from sources like genomic, proteomic, chemical, and clinical datasets acquired from public databases and experimental studies.[20] The accessibility of large-scale datasets is crucial for training AI models and allowing data-driven decision-making. Next to data collection, is **data preprocessing** that includes cleaning, normalization, integration, and feature extraction.[21] This phase confirms that the data is appropriate for examination and cuts the noise that might affect model performance. In general AI algorithms depend on heavily on high-quality data, creating preprocessing phase is essential component of the pipeline. The pipeline further advancements in to **target identification**, where AI models assess biological data to recognise specific disease-related targets.[4] Techniques like machine learning and network analysis are deployed to select targets based on their prospective therapeutic effect. Further application is **hit discovery and screening**, where virtual screening methods are engaged to recognize suitable candidate leads that interact with the designated targets.[26]

Once after identification of candid leads, the net process begins with **lead optimization**, where AI is to redefine molecular structures to expand potency, selectivity, and pharmacokinetic properties.[27] Techniques like molecular docking, quantitative structure–activity relationship (QSAR) modeling, and deep learning are normally deployed in this phase. AI-driven optimization results in decrease of experimental iterations that are required. This is followed by next application that involves **preclinical and clinical development**, where AI is used in predicting toxicity, safety assessment, and trial design[21,28] By assessing historic clinical data, AI supports in predicting potential outcomes and recognize appropriate patient populations for clinical trials. This improves the success rate and decrease the timeframe for early drug development.

Lastly, the pipeline accomplishes with **drug candidate selection**, where the best promising candid leads are selected for further validation and followed by commercialization.[21] AI assists in positioning candid leads based on multiple criteria that includes efficacy, safety, and manufacturability. At the end Figure 2 clearly demonstrates that the continuous and interrelated nature of the drug discovery process, where each step is improved by AI technologies. The integration of AI into drug discovery pipeline allows faster decision-making, lowers budget, and increases success rate ratio of drug development.[5,22]

**AutoGrow4 Algorithm for Lead Optimization**

Genetic mutations and play a major role in the progression of various diseases and disorders.[19,30] For instance mutations are responsible for the progression of cancers reported in various studies[30-32] Similarly meta-genomics is driven by microorganisms which regulate various bio-geo cycles.[33] Recent studies demonstrated they regulate gut biome too.[34] Modern sciences like Genetics, Genomics and Meta-genomics connected with AI play a key role in well understanding the disease and disorders and also supports in drug discovery. Figure 3 reveals the workflow of the AutoGrow4 algorithm, which operates genetic algorithms (GA) for central core optimization in drug discovery. Genetic algorithms are generated by the principles of natural selection and evolution, allowing the production of optimized solutions through complete iterative processes.[35-36] The methodology starts with **input data** that consists of molecular structures and information related to biological activity. The molecules aid as the early population for the optimization process. The next phase is **molecular representation**, where chemical structures are transformed into machine-readable formats appropriate for computational analysis.[37] This conversion is crucial for allowing AI algorithms to process molecular data efficiently.

The central core of the process encompasses a **generative model**, which makes new molecular structures based on learned patterns from the input data.[38] Techniques like variational autoencoders and deep learning models are regularly employed to produce novel analogs with better properties. This phase magnifies the chemical space and enhances the likelihood of recognizing powerful therapeutic candidates. Subsequent generation, the therapeutic candidates undergo **filtering and scoring**, where they are assessed depending upon on the predefined criteria's like drug-likeness, binding affinity, and toxicity.[39] Molecular docking and QSAR models are frequently employed to study the interaction between the generated candid leads and the target protein. This phase certifies that only promising therapeutic candidates are reserved for further investigations. Further, next phase clarifies about **selection and iteration**, where the promising therapeutic candidates are selected and employed to generate the next generation of novel candid leads through crossover and mutation operations.[40] This iterative process lasts until optimal solutions are accomplished.

Lastly, the algorithm generates **suggested analogs**, which are optimized new candid leads with improved pharmacological properties. These candid leads are further subjected to experimental validation and development.[40] In conclusion Figure 3 highlights how genetic algorithms and AI techniques might proficiently discover the vast chemical space and optimize lead candid leads. This method significantly decreases the time and budget linked with traditional lead optimization approaches while refining the likelihood of success.[36,39]

**Figure 1. Applications of Artificial Intelligence in Drug Discovery**


**Figure 2. AI-Driven Pipeline in Drug Discovery**




**Figure 3. AutoGrow4 Algorithm for Lead Optimization**



## CONCLUSION

Thus, AI is transforming the field of drug discovery by increasing efficacy, accuracy, and scalability across all steps of the process. As demonstrated in the figures, AI plays a key central role in target identification, hit discovery, lead optimization, and clinical development. Further, the integration of machine learning, deep learning, and genetic algorithms permits the assessment of complex datasets and the production of novel drug candid leads with improved properties.[5,22] AI-driven pipelines reorganises the drug discovery process by decreasing the dependence on traditional trial-and-error methods and allowing data-driven decision-making. Furthermore, advanced algorithms like AutoGrow4 establishes the prospection of AI in optimizing molecular structures and also speed up the process of candid lead development.[35-36] In spite of these advancements, tasks like data quality, model interpretability, and regulatory considerations stay significant. Answering these tasks through explainable AI and enhanced data integration strategies will be crucial for the successful operation of AI in pharmaceutical research. Overall, AI signifies a transformative tool that is redesigning the future of drug discovery. Its continuous development and integration are expected to considerably increase the success rate ratio of drug development and also contribute to the progression of personalized medicine.[21-22] Thus the above review highlights the importance of AI in drug discovery and development in the present scenario.

## REFERENCES


1. McCarthy J. Artificial intelligence, logic and formalizing common sense. In: Philosophical Logic and Artificial Intelligence. Dordrecht: Springer, 1989; 161–190.
2. McCarthy J. From here to human-level AI. Artif Intell, 2007; 171(18): 1174–1182.
3. IBM. What is artificial intelligence? [Internet]. Available from: https://www.ibm.com/in-en/cloud/learn/what-is-artificial-intelligence.
4. Jeon J, Nim S, Teyra J, Datti A, Wrana JL, Sidhu SS, et al. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med., 2014; 6(7): 1–18.
5. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater., 2019; 18(5): 435–441.
6. Rao PS, Subrahmanyam G, Ramu Sridhar P. Flavonol glycosides from Azadirachta Indica. Drug Intervention Today, 2018; 10(8): 1421-1426
7. Rao PS, Subrahmanyam G. Induction of diabetes by alloxan in male Wistar albino rats –a simplified methodology. Euro J Biomed Pharmacy sci., 2017; 6(13): 68-75.
8. Rao PS, Subrahmanyam G, Bhaskar M. U-HPLC (Ultra-High-pressure Liquid Chromatography) Separation of Indole Alkaloid Strychnine. World J of Pharmacy Res., 2017; 4(11): 1022-35.
9. Rao PS, Prasad MNV. Extraction, Purification and Characterization of Indole Alkaloids from Strychnos Wallachian L. – an Endangered Medicinal Plant from India. Medici Aroma Plant Sci Biotech, 2008; 2: 63-67.
10. Rao PS, Ramanadham M, Prasad MNV. Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line - RPMI 8226. Food Chem Toxic, 2009; 47: 283–288.
11. Rao PS, Prasad MNV. The Strychnos nux-vomica root extract induces apoptosis in the human multiple myeloma cell line-U266B1. Cell Biochem Biophys, 2013; 66: 443–450.
12. Satyanand V, Reddy CB, RamaMohan P, Kumar MR, Narayanaswamy DL, Seelam A, Ramalingam K, Rao PS. Effects of Garlic extract (Allium sativum) in combination with Amlodipine in mild to moderate essential hypertensive patients: An Open randomized parallel-group study. J Pharmacy Res Dev., 2013a; 2(4): 181-188.
13. Satyanand V, Venkata Krishnan, Ramalingam K, Rao PS, Priyadarshini S. Blockade of voltage-dependent calcium channels lowers the high blood pressure through ginger Int J Analy, Pharmace Biomed Sci., 2013b; 2(1): 64-66.
14. Satyanand V, Venkat Krishnan, Madhavi D, Revathi, Indira S, Shaik AB, Rao PS. The effect of peppermint juice for indigestion among old age people- A preliminary study. J Pharmacy Res Dev., 2013c; 2(7): 238-243.
15. Rao PS, Muvva C, Geethanjali K, Babu BS, Kalashikam R. Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioinformation, 2012; 8(17): 834-837.
16. Bola BR, Rao PS, Satish S. Ligand Docking Based Identification of Novel Drug Analog for an Effective Treatment against Filaria, Haya: Saudi J. Life Sci., 2017; 2(9): 335-348.
17. Avinash A, Swarupa SS, Siva K, Sirisha D, Riyaz S, kumar ND, Sreenivasulu M, Rao PS. Design and Evaluation of Famotidine Floating Tablets. Int J Innov Pharmace Res., 2015; 6(1): 440-445.
18. Hymavathi, R, Suresh, G, Sumanth, K.M, Swapna, V.K, Sravanthi, M, Rao, P.S, Manjula, B, Varadacharyulu, N. The therapeutic effect of green tea extract on alcohol-induced hepatic mitochondrial DNA damage in albino Wistar rats. J Adv Res., 2017; 8(3): 289-295.
19. Sravanthi M, Neelam A, Devalaraju RS, Trivedi KVSR, Srinivasulu C , Tamanam RR Suresh G, Rao PS, Role of GSTP1 functional polymorphisms in molecular pathogenesis of colorectal cancer.

Human Gene, 2024; 42. 201335. 10.1016/j.humgen.2024.201335
20. Holmes J, Sacchi L, Bellazzi R. Artificial intelligence in medicine. Ann R Coll Surg Engl, 2004; 86: 334–338.
21. Miles JC, Walker AJ. The potential application of artificial intelligence in transport. IEE Proc Intell Transp Syst., 2006; 153(3): 183–198.
22. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today, Jan. 2021; 26(1): 80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022
23. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today, 2019; 24(3): 773–780.
24. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol, 2011; 162(6): 1239–1249.
25. Zhang, K., Yang, X., Wang, Y. et al. Artificial intelligence in drug development. Nat Med., 2025; 31: 45–59. https://doi.org/10.1038/s41591-024-03434-4
26. Sellwood MA, Ahmed M, Segler MHS, Brown N. Artificial intelligence in drug discovery. Future Med Chem., 2018; 10(17): 2025–2028.
27. Zhu H. Big data and artificial intelligence modeling for drug discovery. Annu Rev Pharmacol Toxicol, 2020; 60: 573–589.
28. Ciallella HL, Zhu H. Advancing computational toxicology in the big data era by artificial intelligence. Chem Res Toxicol, 2019; 32(4): 536–547.
29. Askr H, Elgeldawi E, Aboul Ella H, Elshaier YAMM, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev., 2023; 56(7): 5975–6037.
30. Suresh G, Gopi Krishna S, Nayudu N, Sravanthi M, Rao PS, Kumar VKM, Sowdamani G, Rudramadevi K, Nagesh N, Manjula B, Kondaiah K, Varadacharyulu N (2014) Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a case control study. Tumor Bio doi 10.1007/s13277-014-2505-9.
31. Suresh G, Sravanthi M, Bulle S, Dasi D, Prathap BN, Bramhachari PV, Nagesh N, Shivaji S, Bhanoori M, Rao RT, Rao PS, Varadacharyulu N (2016a) Manganese-superoxide dismutase (Mn-SOD) overexpression is a joint event in colorectal cancers with mitochondrial microsatellite instability. Tumor Biol 2-4: doi 10.1007/s13277-016-4918-0.
32. Suresh G, Bulle S, Sravanthi M, Krishna MT, Nagesh N, Manjula B, Varadacharyulu N, Rao PS (2016) Association of Mitochondrial Displacement Loop Polymorphisms with Risk of Colorectal Cancer in South Indian Population. Mitochondrial DNA. doi.org/10.3109/24701394.2016b.1160076.
33. Singh S, Kotakonda A, Kapardar R, Kankipati H, Rao PS, Mambatta PS, Vetaikorumagan SR, Gundlapally S, Nagappa R, Shivaji S. Response of bacterioplankton to iron fertilization of the Southern Ocean, Antarctica. Front. Microbiol, 2015; 6: 863. Doi: 10.3389/fmicb.2015.00863
34. Avuthu N, Guda C. Meta-Analysis of Altered Gut Microbiota Reveals Microbial and Metabolic Biomarkers for Colorectal Cancer. Microbiol Spectr, Aug. 31, 2022; 10(4): e0001322. doi: 10.1128/spectrum.00013-22
35. Devillers J. Genetic algorithms in molecular modeling. San Diego: Academic Press, 1996.
36. Douguet D, Thoreau E, Grassy G. A genetic algorithm for automated drug design. J Comput Aided Mol Des., 2000; 14: 449–466.
37. Perez-Castillo Y, Lazar C, Taminau J, Froeyen M, Cabrera-Pérez MA, Nowé A. GA-based QSAR modeling. J Chem Inf Model, 2012; 52: 2366–2386.
38. Sun G, Fan T, Sun X, Hao Y, Cui X, Zhao L, et al. QSAR and ML prediction of methyltransferase inhibitors. Molecules, 2018; 23: 2892.
39. Spiegel JO, Durrant JD. AutoGrow4: an open-source genetic algorithm. J Cheminform2020; 12: 1–16.
40. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands. J Mol Recognit, 1996; 9: 1–5.